Item 8.01. Other Events.

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) collaborates in the development and commercialization of RELISTOR, has informed Progenics that global net sales of RELISTOR for the current year through the first quarter of 2009 were $1.9 million. RELISTOR sales are growing from a modest base as Wyeth works to build awareness of its utility in addressing opioid-induced constipation in palliative care and pursues opportunities to expand its use into additional patient settings. New educational and promotional programs are ongoing, including focused regional initiatives implemented with physicians, caregivers and nurses. To date, RELISTOR has been launched in 19 markets including the U.S., Canada, 14 European Union member states, Australia, Venezuela and Chile. Launches are planned for 2009 in 13 additional markets, including Spain, Italy, France, Argentina and Brazil, the largest individual markets after the U.S.

---